Clinical trials: Mismatch Repair- Deficient Rectal Cancer
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer
- Trial name
- NCT06625515
- Testing
- ATX-559
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Accent Therapeutics
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it…
- Trial name
- NCT02997228
- Testing
- Atezolizumab, Bevacizumab, Biospecimen Collection
- Where
- 445 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer, Adenocarcinoma of Rectum
ABCSG R07 Rectal Cancer Registry
In Austria, patients with rectal cancer that has not spread to other parts of the body are typically treated with either total neoadjuvant therapy (TNT) or immunotherapy, depending on their microsatellite status (DNA repair…
- Trial name
- ABCSG R07 RCR (NCT07780305)
- Where
- 3 sites in Austria
- Volunteers
- 600 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Colorectal Cancer
Tislelizumab in People With Colorectal Cancer
The researchers are doing this study to find out whether tislelizumab is an effective treatment for people with colorectal cancer who are living in Nigeria. The researchers will also look at the safety of the study drug.
- Trial name
- NCT06529523
- Testing
- Tislelizumab
- Where
- 3 sites in United States, Nigeria
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Cancer, Advanced Solid Tumor
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis
- Trial name
- NCT06362369
- Testing
- Alintegimod, Ipilimumab, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 126 people
- Sponsor
- 7 Hills Pharma, LLC
Immune-related Adverse Event, Neoadjuvant Therapy
Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer
This study aims to explore the optimal number of cycles of PD-1 monotherapy required at minimum, under the premise of ensuring pathological complete response (pCR) among patients with dMMR/MSI-H rectal cancer.
- Conditions
- Immune-related Adverse Event, Neoadjuvant Therapy, dMMR Colorectal Cancer
- Trial name
- NCT06613165
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xijing Hospital
Colorectal Cancer, Microsatellite Instability High
Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer
The PICC-3 study is a multicentre, single-arm, phase II trial evaluating toripalimab plus celecoxib in patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer.
- Conditions
- Colorectal Cancer, Microsatellite Instability High, Mismatch Repair Deficiency
- Trial name
- PICC-3 (NCT06903858)
- Testing
- Toripalimab plus celecoxib, Non-operative management, Curative-intent surgery
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Sun Yat-sen University
Colorectal Carcinoma
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
In this open-label phase III study, patients with local advanced colon cancer (TanyN+ ,M0, dMMR/MSI-H, at least 10cm from the anus verge)will be scheduled to Group A: receive anti-PD-1 antibody alone (8 cycles, 200mg iv drip Q3W)…
- Trial name
- NCT05236972
- Testing
- Sintilimab, Oxaliplatin, capecitabine
- Where
- China
- Volunteers
- 323 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Cancer
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or…
- Trial name
- CheckMate 8HW (NCT04008030)
- Testing
- Ipilimumab, Oxaliplatin, Leucovorin
- Where
- 157 sites in United States, Argentina and 22 more
- Volunteers
- 839 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors, Colorectal Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214…
- Trial name
- NCT06004245
- Testing
- VVD-133214, Pembrolizumab, Bevacizumab
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 280 people
- Sponsor
- Vividion Therapeutics, Inc.
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients
Total neoadjuvant treatment (TNT) including radiotherapy and induction or consolidation systemic chemotherapy has become the standard treatment for patients with stage II and III rectal adenocarcinoma.
- Trial name
- PREDIR-NEOREC (NCT06762405)
- Testing
- radiotherapy, Dostarlimab, Biological study on circulating tumor DNA (optional for the patient)
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Metastatic Colorectal Cancer
Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
The POLE mutations represent high somatic mutation loads in patients with colorectal cancer, especially in those with MMR proficient or MSS, therefore, tumors harbouring POLE mutations might be susceptible to immune checkpoint…
- Trial name
- NCT03150706
- Testing
- Avelumab
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Asan Medical Center
Colorectal Cancer
Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer
The main purpose of this study was to help meet the medical needs of people in China with certain types of solid tumors that have specific genetic changes called microsatellite instability-high (MSI-H) or deficient mismatch…
- Trial name
- NCT05116085
- Testing
- Tislelizumab
- Where
- 8 sites in China
- Volunteers
- 33 people
- Sponsor
- BeiGene
Colorectal Cancer, Mismatch Repair-deficient (dMMR)
Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer
Colorectal cancer (CRC) is one of the most common malignant tumours of human beings. Mismatch Repair-deficient (dMMR)/ Microsatellite Instability-high (MSI-H) CRC is a specific subtype of CRC, which accounts for approximately 15%…
- Conditions
- Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy
- Trial name
- NCT05371197
- Testing
- Neoadjuvant therapy with PD-L1 inhibitor
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Anti-PD-1 Antibody, Radiotherapy
Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
This prospective, single-arm study is conducted to investigate the safety and efficacy of Sintilimab combined with hypofractionated radiotherapy in patients with microsatellite instability-high (MSI-H)/ DNA mismatch…
- Conditions
- Anti-PD-1 Antibody, Radiotherapy, Rectal Cancer, MSI-H
- Trial name
- NCT04636008
- Testing
- Sintilimab, Hypofractionated Radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Colorectal Cancer
Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer
In this phase II study patients with stage II-III MSI/dMMR colorectal adenocarcinoma with no signs of distant metastases will be treated with immunotherapy (prolgolimab). The duration of treatment is 6 months (12 cycles)
- Trial name
- NCT06428487
- Testing
- Prolgolimab
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Lynch Syndrome, Hereditary Nonpolyposis Colorectal Cancer
Liquid Biopsy Biomarkers for Endoscopic Surveillance in Lynch Syndrome
Lynch syndrome (LS) is an autosomal dominant hereditary condition that markedly increases the risk of colorectal cancer (CRC) and other malignancies.
- Conditions
- Lynch Syndrome, Hereditary Nonpolyposis Colorectal Cancer, HNPCC, Colorectal Cancer (CRC)
- Trial name
- BioLynch (NCT07838246)
- Testing
- Study procedures
- Where
- Italy
- Volunteers
- 109 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Colorectal Cancer
Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer
Colorectal cancer is one of the most common malignant tumors, accounting for approximately 10% of new cancer cases and cancer-related deaths worldwide each year.
- Trial name
- NCT06698757
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Yugui Lian
Colorectal Cancer, Gastric Cancer
Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers
It is planned to study the effectiveness of low-dose immunotherapy (IT) nivolumab 40 mg for either 2 courses of therapy or 6 courses as preoperative therapy in patients with dMMR/MSI locally advanced CRC.
- Trial name
- NIVO402025 (NCT07542262)
- Testing
- Low-dose nivolumab, Low-dose nivolumab with/without chemotherapy, Low-dose nivolumab combined with chemotherapy
- Where
- Russia
- Volunteers
- 128 people
- Sponsor
- Blokhin's Russian Cancer Research Center